首页> 美国卫生研究院文献>mAbs >In vitro and in silico assessment of the developability of a designed monoclonal antibody library
【2h】

In vitro and in silico assessment of the developability of a designed monoclonal antibody library

机译:在体外和计算机模拟中评估设计的单克隆抗体库的可开发性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite major advances in antibody discovery technologies, the successful development of monoclonal antibodies (mAbs) into effective therapeutic and diagnostic agents can often be impeded by developability liabilities, such as poor expression, low solubility, high viscosity and aggregation. Therefore, strategies to predict at the early phases of antibody development the risk of late-stage failure of antibody candidates are highly valuable. In this work, we employ the in silico solubility predictor CamSol to design a library of 17 variants of a humanized mAb predicted to span a broad range of solubility values, and we examine their developability potential with a battery of commonly used in vitro and in silico assays. Our results demonstrate the ability of CamSol to rationally enhance mAb developability, and provide a quantitative comparison of in vitro developability measurements with each other and with more resource-intensive solubility measurements, as well as with in silico predictors that offer a potentially faster and cheaper alternative. We observed a strong correlation between predicted and experimentally determined solubility values, as well as with measurements obtained using a panel of in vitro developability assays that probe non-specific interactions. These results indicate that computational methods have the potential to reduce or eliminate the need of carrying out laborious in vitro quality controls for large numbers of lead candidates. Overall, our study provides support to the emerging view that the implementation of in silico tools in antibody discovery campaigns can ensure rapid and early selection of antibodies with optimal developability potential.
机译:尽管抗体发现技术取得了重大进步,但是单克隆抗体(mAb)成功开发为有效的治疗剂和诊断剂通常会受到可开发性责任的阻碍,例如不良表达,低溶解度,高粘度和聚集。因此,在抗体开发的早期阶段预测候选抗体晚期失败风险的策略非常有价值。在这项工作中,我们使用计算机模拟溶解度预测器CamSol设计一个库,该库包含17个预测的人源化mAb变异体,这些变异体预计可跨越广泛的溶解度值,并且我们将通过一系列常用的体外和计算机模拟来检查其可开发性潜力分析。我们的结果证明了CamSol能够合理地增强mAb的可开发性,并提供了相互之间的体外可开发性测量结果以及资源密集型溶解度测量结果的定量比较,以及提供了可能更快,更便宜的替代方法的计算机预测器。我们观察到了预测的和实验确定的溶解度值之间的强相关性,以及使用一组探索非特异性相互作用的体外可发育性测定所获得的测量值之间的强相关性。这些结果表明,计算方法具有减少或消除对大量潜在候选人进行费力的体外质量控制的潜力。总体而言,我们的研究为新兴观点提供了支持,即在抗体发现活动中实施计算机模拟工具可以确保快速,尽早选择具有最佳开发潜力的抗体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号